Incannex Healthcare Stock Australian S.E.
Stocks
IHL
AU000000IHL8
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 44.93M 31.61M 28.31M 26.04M 23.6M 44.11M 3B 311M 125M 1.58B 119M 116M 4.98B | P/E 2027 * |
-0.94x | P/E 2028 * | -0.9x |
|---|---|---|---|---|---|
| Enterprise Value | 44.93M 31.61M 28.31M 26.04M 23.6M 44.11M 3B 311M 125M 1.58B 119M 116M 4.98B | EV / Sales 2027 * |
-
| EV / Sales 2028 * | - |
| Free-Float |
88.23% | Yield 2027 * |
-
| Yield 2028 * | - |
| 1 day | -10.87% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joel Latham
CEO | Chief Executive Officer | 37 | 01/01/2016 |
Joseph Swan
DFI | Director of Finance/CFO | 35 | 29/02/2024 |
Luigi Barbato
CTO | Chief Tech/Sci/R&D Officer | 63 | 21/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Troy Valentine
CHM | Chairman | 52 | 01/11/2023 |
Peter Widdows
BRD | Director/Board Member | 60 | 01/11/2023 |
Joel Latham
BRD | Director/Board Member | 37 | 01/01/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.87% | -31.67% | - | - | 31.61M | |
| -0.62% | -1.87% | +42.87% | +67.17% | 63.77B | |
| -2.01% | +1.41% | +11.47% | +70.74% | 56.37B | |
| +0.54% | +2.02% | +20.10% | +102.38% | 54.62B | |
| -0.98% | -2.74% | +24.42% | +39.72% | 44.06B | |
| -0.39% | -1.37% | +17.29% | +100.92% | 42.11B | |
| -0.98% | +3.13% | +219.67% | +796.74% | 41B | |
| -4.56% | +27.40% | +102.52% | +91.29% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +47.05% | 32.82B | |
| +0.06% | +20.12% | -39.80% | +348.26% | 24.7B | |
| Average | -1.81% | +7.54% | +45.90% | +184.92% | 43.82B | |
| Weighted average by Cap. | -0.81% | +5.44% | +46.57% | +167.02% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -43.34M -30.49M -27.31M -25.12M -22.76M -42.54M -2.9B -300M -120M -1.52B -114M -112M -4.8B | -45.65M -32.12M -28.76M -26.46M -23.97M -44.81M -3.05B -316M -127M -1.6B -121M -118M -5.06B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
